BioBreakthroughs

Join us on the latest episode! Our Guest: Jay Srinivasan, CEO of Truvian What you'll get out of this episode: Discussing breakthroughs in healthcare diagnostics Insights on integrating technology in healthcare Truvian's mission: accessible and affordable healthcare Focus on early detection and intervention in medical testing Future vision for healthcare accessibility and efficiency To learn more a...

Join us on the latest episode! Our Guest: J.D. Mowery, CEO of KBI Biopharma What you'll get out of this episode: Mowery's progression from the chemical industry to biopharma leadership. Exploration of Mowery's experiences in the industry. KBI BioPharma: Insights into the company's impact and role in the biopharmaceutical industry. Discussion on KBI BioPharma's international facilities and outreach...

Join us on the latest episode! Our Guest: Raj Indupuri, CEO of eClinical Solutions What you'll get out of this episode: Learn how AI optimizes clinical trial design and patient recruitment Explore the impact of AI on reducing drug development costs and timelines Understand the advancements toward personalized medicine Dive into the challenges and opportunities of adopting AI in life sciences Get i...

Join us on the latest episode! Our Guest: Rafael Fantauzzi, Chief Diversity, Equity, and Inclusion Officer at Boehringer Ingelheim. What you'll get out of this episode: Understanding DEI: Diversity, Equity, and Inclusion explained  Cultivating Inclusion: Building trust and embracing inclusive behaviors Collaborative Success: How collaboration fuels progress Staying Informed: The importance of keep...

Join us on the latest episode! Our Guest: Simon Allen, Former CEO, Anebulo Pharmaceuticals What you'll get out of this episode: Journey from biochemistry to sell-side biotech business development. Current treatment landscape for ACI and the limitations therein. Introduction to ANEB-001, a promising antidote aimed at the CB1 receptor to counter cannabinoid overload. Impact of synthetic cannabinoids...

Join us on the latest episode! Our Guest: Dr. Helen Torley, President & CEO at Halozyme What you'll get out of this episode: Introduction to Dr. Helen Torley, CEO and president of Halozyme. Halozyme's mission to reduce treatment burdens for patients. The revolutionary Enhanze technology: Transforming IV infusions to subcutaneous injections. The significant impact of Halozyme's innovations on h...

Join us on the latest episode! Our Guest: Marisa Cruz, M.D. Chief Medical Officer at Empatica What you'll get out of this episode: Exploring Dr. Cruz's background in FDA and her transition to the private sector. Overview of Empatica: Foundation, mission, and their cutting-edge Health Monitoring Platform. The value of digital biomarkers in research. Advancements in remote patient monitoring and its...

Join us on the latest episode! Our Guest: Raquel Izumi, President & COO at Vincerx Pharma Inc What you'll get out of this episode: Raquel's academic background & introduction to drug development. The inspiration drawn from personal experiences and influential figures in the biotech industry. Challenges of co-founding multiple companies. The innovation behind Vincerx Pharma. The potential o...

Join us on the latest episode! Our Guest: Javier Swarcberg, CEO of Spruce Biosciences What you'll get out of this episode: Dive deep into the world of Congenital Adrenal Hyperplasia (CAH) treatments and drug development. Understand the challenges and rewards of addressing rare diseases, especially in pediatrics. Javier Szwarcberg discusses Spruce's innovative Tildesophon and its potential impact o...

Join us on the latest episode! Our Guest: Paul Billings, CEO And Director Of Biological Dynamics What you'll get out of this episode: Harvard MD/PhD, former physician, current CEO focusing on personalized medicine. Biological Dynamics Overview: 10-year-old company, isolates plasma particles from minimal blood samples for diagnostics. Aiming for early-stage detection of pancreatic cancer to improve...

Join us on the latest episode! Our Guest: Simon Arkell, CEO and Co-Founder of Synthetica Bio What you'll get out of this episode: - Simon Arkell, CEO of Synthetica Bio, sheds light on biopharma's future - Originally an Australian athlete, Arkell became a U.S.-based entrepreneur, focusing on machine learning, data analytics, and patient care. - His standout contribution was through DeepLens in prec...

Join us on the latest episode! Our Guest: Ravi Samavedam, Chief Innovation Officer At Azzur Group What you'll get out of this episode: - Ravi Samavedam of Azzur Group discusses lab space solutions for biotech. - Azzur Group's clean rooms on demand address lab space shortages, offering flexible configurations. - Their model eases GMP compliance burden by managing facilities and support services. -...

Join us on the latest episode! Our Guest: Pascal Touchon, President and CEO at Atara Biotherapeutics What you'll get out of this episode: - Backstory on Pascal - Leading CAR-T at Novartis and Atara, focusing on lymphoma. - Creation of EBV T Cell Platform for cancer and autoimmune diseases. - The milestones for Ebalo, including European approval. - Impacting cell therapy with validation, quality ma...

Join us on the latest episode! Our Guest: Jason Bock, CEO At CTMC What you'll get out of this episode: - Jason’s path to founding CTMC - An overview of CTMC - CTMC’s mission - CTMC’s unique partnership with MD Anderson - The exciting opportunities at CTMC - CTMC’s mission to help patients & advancing novel scientific breakthroughs into medicines to ultimately end cancer - The future of CTMC &a...

Join us on the latest episode! Our Guest: Pete O'Heeron, Chairman/CEO/Founder, FibroBiologics What you'll get out of this episode: Pete's background Overview of FibroBiologics Their fibroblast technology platform and its therapeutic potential What his formula has been for growing and scaling the team and product pipeline Key takeaways from #BIO2023 What trends do he sees developing right now in re...

Join us on the latest episode! Our Guest: Nolan Townsend, CEO of LEXEO Therapeutics What you'll get out of this episode: Can you tell us about your background and what led you to LEXEO? What product candidates are development at LEXEO? How is what LEXEO is developing different than the current treatments in the neurological and cardiac spaces? At BIO you spoke to the topic of accelerated approval,...

Join us on the latest episode! Our Guest: Sandra von Meier, Head of Business Development at Debiopharm What you'll get out of this episode: - Sandra's background - Overview of Debiopharm - Tell us about Debiopharm’s approach to drug development. How does it work with startups to enhance innovation and expedite clinical trial timelines? - What steps can companies take to improve patient quality of...

This exciting episode is a conversation with David Esposito, President and CEO of ONL Therapeutics! We had the pleasure of hosting David Esposito, a visionary leader in the field of biotechnology as the President and CEO of ONL Therapeutics. Join us as we dive deep into the fascinating world of retinal diseases and explore the future of biotech! In this episode, we covered: - David's inspiring bac...

Our Guest: Richard Brandon, Chief Scientific Officer at Immunexpress What you'll get out of this episode: Richard's background Overview of Immunexpress The impact of a lack of reliable sepsis diagnostics SeptiCyte technology What's next? Our sponsors for this episode are Sage Growth Partners Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus o...

Our Guest: Rohit Nambisan, CEO & Co-Founder at Lokavant What you'll get out of this episode: Rohit's background Overview of Lokavant The biggest data challenges in clinical trials today It's mentioned that late-phase trials are now generating 3x more data than 10 years ago. How is Lokavant managing this influx of data? The limitations of legacy systems and processes in handling the data from c...

Our Guest: Joel Morse, CEO at Curavit Clinical Research What you'll get out of this episode: Joel's background Curavit Overview CRO and virtual clinical site services for clinical trials Traditional vs. Decentralized Clinical Trials What the future of this space looks like? Our sponsors for this episode are Sage Growth Partners Sage Growth Partners accelerates commercial success for healthcare org...

Our Guest: Chris Bahl, Co-Founder, President & Chief Scientific Officer at AI Proteins What you'll get out of this episode: Bahl's background Overview of AI Proteins How they are utilizing computational protein design to engineer synthetic miniproteins therapeutics that can bind to any target The process and challenges Key differentiators Their impact on the future of medicine Our sponsors for...

Our Guest: #2 - Spiro Rombotis, CEO at Cyclacel Pharmaceuticals What you'll get out of this episode: Rombotis's background and an overview of Cyclacel Which part of the cell cycle they're targeting? What their leading candidates are, and the current clinical trial statuses of each. What makes their CDK inhibitor strategy unique compared to other biopharmaceutical companies? Their PLK1 program Near...

Our Guest: Kendalle Burlin O’Connell, Esq., President & CEO at MassBio What you'll get out of this episode: Kendalle's career journey Workforce training program ResearcHERS Trends to watch Our sponsors for this episode are Sage Growth Partners Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thriv...